Fortress Biotech, Inc. (FBIO) stock
FBIONasdaqPharmaceutical PreparationsFiscal year ends December 31Also trades as FBIOP
$1.99−0.02 (-1.00%)
Close on Nov 12, 2026Market cap $73.19MP/E –Yield –
Fortress Biotech gross margin
Gross margin is gross profit as a percentage of revenue.
Fortress Biotech's gross margin for the twelve months ending Jun 30, 2026 was 65.6%. For fiscal 2025 it was 66.9%, against 63.8% the year before. The highest annual figure on record is 100.0% in fiscal 2015.
Annual gross margin
| Period | Period end | Value | Change (pts) |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | 66.9% | +3.1 |
| FY2024 | Dec 31, 2024 | 63.8% | −9.1 |
| FY2023 | Dec 31, 2023 | 72.9% | +13.5 |
| FY2022 | Dec 31, 2022 | 59.4% | +6.0 |
| FY2021 | Dec 31, 2021 | 53.4% | −14.6 |
| FY2020 | Dec 31, 2020 | 68.0% | −3.3 |
| FY2019 | Dec 31, 2019 | 71.2% | −6.0 |
| FY2018 | Dec 31, 2018 | 77.2% | −1.6 |
| FY2017 | Dec 31, 2017 | 78.8% | −16.4 |
| FY2016 | Dec 31, 2016 | 95.2% | −4.8 |
| FY2015 | Dec 31, 2015 | 100.0% | – |
Quarterly gross margin
Change is against the same quarter a year earlier.
| Period | Period end | Value | Change (pts) |
|---|---|---|---|
| Q2 FY2026 | Jun 30, 2026 | 67.2% | −2.7 |
| Q1 FY2026 | Mar 31, 2026 | 61.2% | −2.3 |
| Q4 FY2025 | Dec 31, 2025 | 66.2% | −2.9 |
| Q3 FY2025 | Sep 30, 2025 | 67.4% | −2.1 |
| Q2 FY2025 | Jun 30, 2025 | 69.9% | +8.4 |
| Q1 FY2025 | Mar 31, 2025 | 63.5% | +9.6 |
| Q4 FY2024 | Dec 31, 2024 | 69.0% | −19.7 |
| Q3 FY2024 | Sep 30, 2024 | 69.4% | −12.1 |
| Q2 FY2024 | Jun 30, 2024 | 61.6% | +6.2 |
| Q1 FY2024 | Mar 31, 2024 | 53.9% | +5.8 |
| Q4 FY2023 | Dec 31, 2023 | 88.7% | +35.8 |
| Q3 FY2023 | Sep 30, 2023 | 81.5% | +25.2 |
| Q2 FY2023 | Jun 30, 2023 | 55.3% | −4.3 |
| Q1 FY2023 | Mar 31, 2023 | 48.1% | −17.6 |
| Q4 FY2022 | Dec 31, 2022 | 53.0% | +5.1 |
| Q3 FY2022 | Sep 30, 2022 | 56.3% | +9.3 |
| Q2 FY2022 | Jun 30, 2022 | 59.6% | +1.5 |
| Q1 FY2022 | Mar 31, 2022 | 65.7% | −0.6 |
| Q4 FY2021 | Dec 31, 2021 | 47.9% | −21.0 |
| Q3 FY2021 | Sep 30, 2021 | 47.0% | −17.3 |
| Q2 FY2021 | Jun 30, 2021 | 58.1% | −8.9 |
| Q1 FY2021 | Mar 31, 2021 | 66.3% | −4.2 |
| Q4 FY2020 | Dec 31, 2020 | 68.9% | +0.8 |
| Q3 FY2020 | Sep 30, 2020 | 64.3% | −8.0 |
| Q2 FY2020 | Jun 30, 2020 | 67.0% | −7.2 |
| Q1 FY2020 | Mar 31, 2020 | 70.5% | −0.4 |
| Q4 FY2019 | Dec 31, 2019 | 68.0% | −14.4 |
| Q3 FY2019 | Sep 30, 2019 | 72.3% | −0.5 |
| Q2 FY2019 | Jun 30, 2019 | 74.2% | −1.3 |
| Q1 FY2019 | Mar 31, 2019 | 70.9% | −4.2 |
| Q4 FY2018 | Dec 31, 2018 | 82.4% | +6.4 |
| Q3 FY2018 | Sep 30, 2018 | 72.8% | −7.1 |
| Q2 FY2018 | Jun 30, 2018 | 75.5% | −4.5 |
| Q1 FY2018 | Mar 31, 2018 | 75.1% | −8.1 |
| Q4 FY2017 | Dec 31, 2017 | 76.1% | −21.0 |
| Q3 FY2017 | Sep 30, 2017 | 80.0% | −15.8 |
| Q2 FY2017 | Jun 30, 2017 | 80.1% | – |
| Q1 FY2017 | Mar 31, 2017 | 83.1% | – |
| Q4 FY2016 | Dec 31, 2016 | 97.0% | – |
| Q3 FY2016 | Sep 30, 2016 | 95.8% | – |
See a number that looks wrong?